- Open Access
In-depth mass spectrometric mapping of the human vitreous proteome
© Aretz et al.; licensee BioMed Central Ltd. 2013
- Received: 15 January 2013
- Accepted: 26 April 2013
- Published: 20 May 2013
Mapping of proteins involved in normal eye functions is a prerequisite to identify pathological changes during eye disease processes. We therefore analysed the proteome of human vitreous by applying in-depth proteomic screening technologies. For ethical reasons human vitreous samples were obtained by vitrectomy from “surrogate normal patients” with epiretinal gliosis that is considered to constitute only negligible pathological vitreoretinal changes. We applied different protein prefractionation strategies including liquid phase isoelectric focussing, 1D SDS gel electrophoresis and a combination of both and compared the number of identified proteins obtained by the respective method. Liquid phase isoelectric focussing followed by SDS gel electrophoresis increased the number of identified proteins by a factor of five compared to the analysis of crude unseparated human vitreous. Depending on the prefractionation method proteins were subjected to trypsin digestion either in-gel or in solution and the resulting peptides were analysed on a UPLC system coupled online to an LTQ Orbitrap XL mass spectrometer. The obtained mass spectra were searched against the SwissProt database using the Mascot search engine. Bioinformatics tools were used to annotate known biological functions to the detected proteins. Following this strategy we examined the vitreous proteomes of three individuals and identified 1111 unique proteins. Besides structural, transport and binding proteins, we detected 261 proteins with known enzymatic activity, 51 proteases, 35 protease inhibitors, 35 members of complement and coagulation cascades, 15 peptide hormones, 5 growth factors, 11 cytokines, 47 receptors, 30 proteins of visual perception, 91 proteins involved in apoptosis regulation and 265 proteins with signalling activity. This highly complex mixture strikingly differs from the human plasma proteome. Thus human vitreous fluid seems to be a unique body fluid. 262 unique proteins were detected which are present in all three patient samples indicating that these might represent the constitutive protein pattern of human vitreous. The presented catalogue of human vitreous proteins will enhance our understanding of physiological processes in the eye and provides the groundwork for future studies on pathological vitreous proteome changes.
- Human eye
- Vitreous proteome
- Eye disease
- Prefractionation strategy
The human vitreous humor is a clear aqueous solution which fills the posterior compartment of the eye, located between the lens and the retina. It occupies about 80% of the volume of the eyeball and comprises 99% water but has a gel-like structure at birth due to a network of collagen fibrils and large molecules of hyaluronic acid. With aging the vitreous undergoes a process of progressive liquefaction so that at the age of 80–90 years more than half of the vitreous is liquid . Vitreous humor contains several low molecular weight solutes including inorganic salts, sugars and ascorbic acid. The total concentration of protein in human vitreous is approximately 1200 μg/ml, of which collagen accounts for 180 μg/ml . Soluble proteins in vitreous humor are thought to originate from plasma by filtration through fenestrated capillaries of the ciliary body stroma via the iris root [3, 4]. However, protein secretion or shedding from posterior chamber tissues, including photoreceptors and the retinal pigment epithelium, may have a significant impact on the pattern of soluble proteins found in the vitreous. Since, as in all other human tissues, a major function of soluble extracellular proteins is maintenance of homeostasis in adjacent tissues, vitreous fluid contains soluble proteins that are necessary to sustain normal ocular morphology and functions. Such important physiological role requires tight control of the qualitative and quantitative composition of the vitreous proteome. Consequently the vitreous in the healthy eye should contain a complex but defined protein mixture. Studies investigating the vitreous proteome provide valuable information for the understanding of ocular biochemistry. Conversely, if the protein composition of the vitreous is central to the health of the human eye, alterations in vitreous protein expression will be on one hand indicative of ocular disease, on the other hand may be actively involved in the pathogenic process. Indeed, a number of vitreous fluid proteins have already been linked to the aetiology of ocular and vitreoretinal disorders [5, 6]. However, we are still far from a detailed understanding of the complex biochemical processes mediated by vitreous proteins, and consequently extensive analysis of the role of vitreous proteome changes in the development of eye diseases is not yet feasible.
Towards a better understanding of vitreous protein composition and functions a number of proteomic analyses have already been conducted. In recent studies only 38 resp. 121 individual proteins were identified in human vitreous humor [7, 8]. By applying different proteomic methods including 2-DE/MALDI-MS, nanoLC-MALDI-MS/MS, and nanoLC-ESI-MS/MS a total of 346 individual proteins were identified in vitreous of a non-diabetic control group . In a recent study 355 proteins were identified by nano-LC-ESI-MS/MS and 206 proteins by antibody-based protein arrays in human aqueous humor whose composition may be similar to the vitreous body . Analysis of aqueous humor collected during routine cataract surgery from otherwise healthy eyes identified 198 unique proteins . However, considering the complexity of other body fluids like blood plasma or cerebrospinal fluid containing thousands of different proteins, it is likely to assume that only the most abundant proteins in the vitreous have been detected up to now. Indeed in the present study applying state-of-the art proteomics technologies we were able to detect more than 1000 different proteins in human vitreous.
Following approval by the ethics review board of the University Hospital Bonn, vitreous material was sampled from patients undergoing elective pars plana vitrectomy for epiretinal gliosis at the Bonn University Eye Hospital. Written consent from the patients was obtained for use of the samples in the present study. Patients with previous vitreoretinal surgery, intravitreal drug injections, or additional vitreoretinal diseases were excluded. During vitrectomy, complete vitreous material diluted in surgical irrigation fluid (balanced salt solution; PuriSol, Carl Zeiss Meditec, Jena, Germany) was collected. Samples were stored frozen at −80°C immediately after surgery until analysis. Contamination with blood during surgery was excluded by haemoglobin ELISA (Bethyl Laboratories; Montgomery, TX, USA). Only samples without detectable haemoglobin were used in this study. The test has a detection limit of 0.27 ng/ml.
Sample processing and fractionation
Before further processing, protein content of the vitreous samples was determined by the Lowry procedure . Protein was precipitated from aliquots of vitreous samples (representing 50 μg of protein for SDS polyacrylamide gel electrophoresis (SDS PAGE) and 1mg for liquid phase isoelectric focussing (liquid phase IEF)) by adding an equal volume of 10% trichloroacetic acid (TCA). After centrifugation (15 min, 15000 g, 4°C) and washing with 1 ml ice-cold acetone the protein pellet was dried for ~10 min in vacuo and resolubilized for SDS PAGE or liquid phase IEF.
For SDS-PAGE vitreous protein precipitate was dissolved in NuPAGE LDS sample buffer and separated on a NuPAGE Novex 4-12% Bis Tris gel (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s instructions. The gel was Coomassie-stained according to the procedure of Kang et al.  and each lane was cut into 26 pieces. Liquid phase IEF was conducted in a ZOOM® IEF Fractionator (Invitrogen). To this end the protein precipitate (1 mg) was dissolved in 900 μl 1.1× IEF Denaturant (7.7 M urea, 2.2 M thiourea, 4.4% CHAPS). Then 10 μl 100× protease inhibitor (90 mM AEBSF, 430 mM EDTA, 8.5 mM Bestatin, 1.4 mM Pepstatin A, 1.1 mM E-64, 1.0 mM Leupeptin) and 10 μl 2 M DTT were added. The mixture was sonicated (10 rounds / 10 s / 50% power), and 10 μl 1 M Tris base were added, followed by an incubation time of 30 min at room temperature (RT). 5.2 μl of dimethylacetamide were added and incubated for further 30 min at RT. Finally 10 μl of ZOOM carrier ampholytes (pH3-10) and 10 μl 2 M DTT were added to the sample solution. The whole mixture was filled up to a final volume of 3.5 ml with IEF denaturant and loaded to the ZOOM IEF fractionator. A trace of bromophenol blue visualized direction of the sample movement. Settings for separation were: current 2 mA, power 2W, voltage 100V for 20 min / 200V for 80 min / 600V for 80 min. Separation yielded 5 fractions of about 650 μl representing pH ranges of 3,0 - 4,6 (fraction 1), 4,6 - 5,4 (fraction 2), 5,4 – 6,2 (fraction 3), 6,2 – 7,0 (fraction 4), 7,0 – 10 (fraction 5). To obtain similar amounts of protein for further separation by SDS PAGE protein was precipitated from 400 μl of fraction 1, 100 μl of fraction 2, 70 μl of fraction 3, 90 μl of fraction 4 and 300 μl of fraction 5 by TCA/acetone as described above.
Preparation of samples for protein identification
Proteins in the individual IEF fractions were reduced, alkylated and digested in solution with trypsin. Briefly, after TCA precipitation, the dried pellet was resuspended in 20 μl 40 mM NH4HCO3. 2 μl DTT (10 mM DTT in NH4HCO3) was added to the solution and proteins were reduced at 45°C for 1 h. Free cysteine residues were alkylated with 1 μl iodoacetamide (55 mM in 40 mM NH4HCO3) for 30 min at 25°C in the dark, followed by the addition of 2.5 μl DTT. The mixture was incubated at 37°C for 15 min in a thermomixer (600 rpm). Afterwards, trypsin (1/100 w/w of precipitated protein amount) was added and proteins were digested at 37°C overnight.
Proteins in the individual gel slices were reduced, alkylated and in-gel digested with trypsin . Briefly, after incubation with 150 μl water at 37°C for 5 min, water was removed (washing step) and gel pieces were shrunk by dehydration with 150 μl water/acetonitrile 50:50 (v/v) at 37°C for 5 min in a thermo mixer (600 rpm). The solution was removed and the proteins were reduced with 100 μl 10 mM DTT in 40 mM NH4HCO3 for 1 h at 56°C. The solution was removed and gel pieces were incubated with 150 μl water for 5 min at 37°C. After removing the solution from the gel plugs proteins were alkylated with 100 μl 55 mM iodoacetamide in 40 mM NH4HCO3 for 30 min at 25°C in the dark, followed by three alternating washing steps each with 150 μl of water and water/acetonitrile 50:50 (v/v) for 8 min at 37°C. Gel pieces were then dehydrated with 100 μl acetonitrile for 1 min at RT, dried for 15 min and subsequently rehydrated with porcine trypsin (sequencing grade, Promega, Mannheim, Germany) with a minimal volume sufficient to cover the gel pieces after rehydration (100 ng trypsin in 40 mM NH4HCO3). Samples were incubated overnight at 37°C.
After overnight digestion the supernatant was collected in PCR tubes while gel pieces were subjected to four further extraction steps. Gel pieces were sonicated for 5 min in acetonitrile/0.1% aqueous TFA 50:50 (v/v). Following centrifugation the supernatant was collected and gel pieces were sonicated for 5 min in acetonitrile. After collecting the supernatant gel pieces were sonicated for 5 min in 0.1% TFA followed by another extraction step with acetonitrile. The combined solutions were dried in a speed-vac at 37°C for 2 h. Peptides were redissolved in 5 μl 0.1% TFA by sonication for 5 min and subsequently analysed by nanoLC ESI-MS/MS.
ESI-MS/MS analysis and database search
Tryptic peptide mixtures were separated using a nanoAcquity UPLC system. A C18 trap column (180 μm × 20 mm) with a particle size of 5 μm was used (Waters GmbH, Eschborn, Germany). Liquid chromatography separation was performed on a BEH130 C18 main-column (100 μm × 100 mm) with a particle size of 1.7 μm (Waters GmbH, Eschborn, Germany) at a flow rate of 0.4 μl / min. Gel slices 1–7, 12–17 and 22–26 were separated by a 1 h gradient whereas slices 8–11 and 18–21 were fractionated by a 2 h gradient. The 1 h gradient was set as follows: from 0 to 4% B in 1 min, from 4 to 40% B in 39 min, from 40 to 60% B in 5 min, from 60 to 85% B in 0.1 min, 6 min at 85% B, from 85 to 0% B in 0.1 min, and 9 min at 0% B. The 2 h gradient started from 0 to 4% B in 1 min, from 4% to 30% in 79 min. The next step was set from 30 to 45% B within 10 min followed by an increase in 10 min of solvent B from 45 to 90% and for a further 10 min at 90% solvent B. After this step the concentration was stepped down to 0% solvent B and continued for 15 min. Solvent A contained 98.9% water, 1% acetonitrile and 0.1% formic acid, solvent B contained 99.9% acetonitrile and 0.1% formic acid. The nanoUPLC system was coupled online to an LTQ Orbitrap XL mass spectrometer (Thermo Scientific, Bremen, Germany).Data were acquired by scan cycles of one FTMS scan with a resolution of 60000 at m/z 400 and a range from 300 to 2000 m/z in parallel with six MS/MS scans in the ion trap of the most abundant precursor ions.
The mgf-files were used for database searches with the MASCOT search engine (Matrix Science, London, UK; version 2.2) against SwissProt database (http://www.expasy.ch/sprot/sprot-top.html Rel. 2011_05). Taxonomy was set to human. The peptide mass tolerance for database searches was 10 ppm and fragment mass tolerance 0.4 Da. Carbamidomethylation of C was set as fixed modification. Variable modifications included oxidation of M and deamidation of N and Q. One missed cleavage site in case of incomplete trypsin hydrolysis was allowed. Ion score cut off was set to 20. Proteins were considered as identified if two unique peptides were detected and at least one peptide had an individual ion score exceeding the MASCOT identity threshold of 26. Identification under the applied search parameters refers to False Discovery Rate (FDR) < 3,5% and a match probability of p<0.05, where p is the probability that the observed match is a random event. We indicated proteins for which only one peptide matched the threshold of 26 by an asterisk in all tables provided in the results section as well as in the supplementary material. Each gel slice was analyzed separately and MS/MS data were merged prior to protein database search.
Web-based tools for classification and functional annotation of all proteins by their GO number were used. First, we used DAVID Bioinformatics Resources (the Database for Annotation, Visualization and Integration Discovery [15, 16]. The SwissProt ID list was pasted and Uniprot IDentifier was chosen to establish a gene list. The function “Functional annotation table” using GO terms (Cellular Component, Molecular Function, Biological Process, Protein Class) were chosen. Second, the classification System PANTHER (Protein ANalysis THrough Evolutionary Relationships) [17, 18], Batch ID upload, was used creating a similar annotation table with the GO terms (CC, MF, BP,PC). Search procedure was again performed by using SwissProt identification numbers.
The GO terms which were in common in both tables were used for annotation of the proteins. “Secreted proteins” were annotated according to DAVID’s SP-PIR-Keywords.
if two or more hits belong to the same INTERPRO family. The task compares all true positive hits of the different protein family databases grouping together those hits, which are members of the same INTERPRO family/domain.
if the motif shows the same order as described in PRINTS or BLOCKS. Both databases characterize a protein family with a group of highly conserved motifs/segments in a well-defined order. The task compares the order of the identified true positive hits with the order described in the corresponding PRINTS or BLOCKS entry. Only hits in correct order are accepted.
All other hits above the trusted thresholds are listed as ‘putative’. They are significant within the domain database searched.
Ethical feasibility largely confines vitreous material sampling for research purposes to individuals that receive vitreous removal surgery (vitrectomy) for medical reasons, i.e. as a treatment for vitreoretinal diseases such as diabetic retinopathy. As vitrectomies are not performed in healthy persons, most previous studies on the vitreous proteome employed control groups of “surrogate normal patients” with diseases such as epiretinal gliosis, vitreomacular traction syndrome, and idiopathic macular hole that are considered to constitute only comparatively minor pathological vitreoretinal changes [9, 20, 21]. In our study, we examined vitreous material from three patients with epiretinal gliosis (also: epiretinal membrane, macular pucker), a disease in which retinal cells form a thin membrane on the inner retinal surface that causes visual distortions and decline . Our study thus presents a catalogue of the vitreous proteome in the absence of neurodegenerative, ischemic, and vasoproliferative retinal changes associated with many other retinal diseases and provides a baseline for future comparative proteomic studies of such pathologies.
Our results clearly indicate that the protein composition of the human vitreous humor is much more complex than might be expected from previous proteome analyses. A very similar protein pattern can be expected for aqueous humor filling the anterior eye chamber between the cornea and lens, since the gel-like vitreous humor consists of 99% fluid and there is a continuous exchange between the aqueous humor and the vitreous humor located in the posterior part of the eye behind the lens. Such exchange is also reflected by the detection of the lens-specific crystallins in the vitreous humor. 262 unique proteins were detected which are present in all three patient samples indicating that these might represent the constitutive protein pattern of human vitreous. However, there also seems to exist a striking heterogeneity between the individual samples, as 236 proteins were only detectable in one sample and 196 proteins were found in two of the three specimen. Such heterogeneity may be a common feature of human biological fluids as exemplified by human plasma which also shows broad interindividual differences, in particular with regard to lower abundance proteins . This should be kept in mind when the vitreous proteome of patients with eye disorders is screened for specific disease markers. In particular, some of the proteins that were not identified in at least two of the three subjects may not represent “normal” vitreous proteins. In general it is difficult to distinguish between the proteins that are actively secreted to the human vitreous and proteins introduced by low-level tissue leakage. The annotation as secreted protein given in Additional file 2: Table S2 and Additional file 3: Table S3 may serve as a rough guideline. Various keratins were detected in the samples. However, in particular the keratins 1, 2, 5, 9, 10 and 14 are known contaminants that may occur during sample preparation . Since collection of the clinical samples in a keratin free environment was not feasible, these keratins might have arrived in the samples through contamination rather than through natural abundance in vitreous humor.
Although we applied a highly sensitive state-of-the-art methodology to map the vitreous proteome, only further prefractionation of the samples enabled detection of very low abundance proteins. Thus applying liquid phase isolelectric focussing as prefractionation strategy in combination with 1D SDS PAGE facilitated a striking increase in the dynamic range of detection, i.e. the number of proteins detected in sample VP2 increased from 434 for the gel separated sample to 916. Consequently liquid phase IEF might also be applied for efficient prefractionation prior to detection by other methods, including Western blotting or ELISA techniques, in studies on very low abundance proteins. On the other hand our results clearly indicate that during prefractionation either by SDS-gel electrophoresis or liquid phase IEF some proteins will be lost. Thus a combination of different prefractionation strategies is necessary to cover the complete vitreous proteome.
Comparison of the map of vitreous proteins obtained in our study with the HUPO plasma proteome indicates that the vitreous proteome strikingly differs from the plasma proteome. Thus considering the complete list of all 1111 proteins detected in the vitreous samples, only about 27% are listed also as plasma proteins. Relating to the 262 “constitutive” vitreous proteins only about 50% are known plasma proteins. Consequently the aqueous phase of human vitreous appears to be a discrete and unique body fluid with only partial overlap to other extracellular fluid body compartments. This is contradictory to the assumption that most protein species of the vitreous originate from plasma. The detection of crystallins may indicate that protein release from the lens could also contribute to the vitreous proteome. However, recent studies indicate that crystallins are also synthesized in the retina. Crystallins may have several metabolic and regulatory functions. Their synthesis is dramatically up regulated by a large range of diseases, including diabetic retinopathy, age-related macular degeneration, uveitis, trauma and ischemia. Further investigations on the origin as well as on normal and pathological functions of crystallins in the vitreous may help to understand the aetiology of the above mentioned disorders . The detection of dermcidin, an antimicrobial peptide commonly considered to be a primitive mechanism of immunity, in human vitreous is another interesting finding . Recently this peptide was also identified in tear fluid . Galectin-1 is an example of a protein with potential adhesion/growth regulatory functions in the eye , but has not been annotated as a plasma protein. Lengsin is an eye lens-specific member of the glutamine synthetase superfamily . Opticin is a classical vitreous protein, where it is associated with humor collagen fibrils . Some of the detected proteins such as retinoschisin and retbindin are specifically secreted by photoreceptor cells [31, 32] which indicates that cells of all retinal layers including the outer retina contribute proteins to the vitreous proteome. A previous analysis of the secretome of cultured human RPE indicates that RPE cells secrete a variety of proteins (73 individual proteins) including extracellular matrix proteins, cell adhesion proteins, complement factors, proteases, protease inhibitors, enzymes and growth factors, that may be involved in normal functions of the eye as well as in the pathogenesis of eye disorders . Therefore a comprehensive in-depth analysis of the RPE secretome and comparison to the vitreous proteome will help to assess the contribution of the RPE to the vitreous proteome composition and function.
Human vitreous appears to be a discrete and unique body fluid with only partial overlap to the plasma proteome. Our findings suggest that vitreous proteome analysis may prove useful in examining all retinal diseases, even those primarily affecting the outer retina such as age-related macular degeneration and most hereditary retinal dystrophies. Altogether this study provides the most comprehensive human vitreous proteome coverage and list reported to date. The protein set has immediate utility for investigators interested in using vitreous samples to study eye disorders, including widespread diseases like age-related macular degeneration or diabetic retinopathies.
In addition a comparison of different prefractionation methods for comprehensive proteome analysis of a largely uncharacterized human body fluid is given with the example of human vitreous, indicating that human vitreous contains a variety of low abundance proteins that were only detectable by employing efficient prefractionation methods like liquid phase isoelectric focussing.
The authors thank Nicole Eter, Claudia Inhetvin-Hutter, Carsten H. Meyer, Steffen Schmitz-Valckenberg, and Peter Charbel Issa for their help with vitreous sampling.
This worked was supported by the Fritz-Tobler-Foundation, Fontanas, Switzerland.
- Le Goff MM, Bishop PN: Adult vitreous structure and postnatal changes. Eye (Lond) 2008, 22: 1214–1222. 10.1038/eye.2008.21View ArticleGoogle Scholar
- Theocharis AD, Papageorgakopoulou N, Feretis E, Theocharis DA: Occurrence and structural characterization of versican-like proteoglycan in human vitreous. Biochimie 2002, 84: 1237–1243.PubMedGoogle Scholar
- Freddo TF, Bartels SP, Barsotti MF, Kamm RD: The source of proteins in the aqueous humor of the normal rabbit. Invest Ophthalmol Vis Sci 1990, 31: 125–137.PubMedGoogle Scholar
- Barsotti MF, Bartels SP, Freddo TF, Kamm RD: The source of protein in the aqueous humor of the normal monkey eye. Invest Ophthalmol Vis Sci 1992, 33: 581–595.PubMedGoogle Scholar
- Funatsu H, Yamashita T, Yamashita H: Vitreous fluid biomarkers. Adv Clin Chem 2006, 42: 111–166.PubMedView ArticleGoogle Scholar
- Holekamp NM: The vitreous gel: more than meets the eye. Am J Ophthalmol 2010, 149: 32–36. 10.1016/j.ajo.2009.07.036PubMedView ArticleGoogle Scholar
- Yamane K, Minamoto A, Yamashita H, Takamura H, Miyamoto-Myoken Y, Yoshizato K, Nabetani T, Tsugita A, Mishima HK: Proteome analysis of human vitreous proteins. Mol Cell Proteomics 2003, 2: 1177–1187. 10.1074/mcp.M300038-MCP200PubMedView ArticleGoogle Scholar
- Koyama R, Nakanishi T, Ikeda T, Shimizu A: Catalogue of soluble proteins in human vitreous humor by one-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electrospray ionization mass spectrometry including seven angiogenesis-regulating factors. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 792: 5–21. 10.1016/S1570-0232(03)00133-8PubMedView ArticleGoogle Scholar
- Kim T, Kim SJ, Kim K, Kang UB, Lee C, Park KS, Yu HG, Kim Y: Profiling of vitreous proteomes from proliferative diabetic retinopathy and nondiabetic patients. Proteomics 2007, 7: 4203–4215. 10.1002/pmic.200700745PubMedView ArticleGoogle Scholar
- Chowdhury UR, Madden BJ, Charlesworth MC, Fautsch MP: Proteome analysis of human aqueous humor. Invest Ophthalmol Vis Sci 2010, 51: 4921–4931. 10.1167/iovs.10-5531PubMed CentralPubMedView ArticleGoogle Scholar
- Bennett KL, Funk M, Tschernutter M, Breitwieser FP, Planyavsky M, Mohien CU, Muller A, Trajanoski Z, Colinge J, Superti-Furga G, Schmidt-Erfurth U: Proteomic analysis of human cataract aqueous humour: Comparison of one-dimensional gel LCMS with two-dimensional LCMS of unlabelled and iTRAQ(R)-labelled specimens. J Proteomics 2011, 74: 151–166. 10.1016/j.jprot.2010.10.002PubMedView ArticleGoogle Scholar
- Lowry OH, Rosegrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193: 265–275.PubMedGoogle Scholar
- Kang D, Gho M, Suh M, Kang C: Highly sensitive and fast protein detection with Coomassie Brilliant Blue in sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Bull Korean Chem Soc 2002, 11: 1511–1512.Google Scholar
- Lossner C, Meier J, Warnken U, Rogers MA, Lichter P, Pscherer A, Schnolzer M: Quantitative proteomics identify novel miR-155 target proteins. PLoS One 2011, 6: e22146. 10.1371/journal.pone.0022146PubMed CentralPubMedView ArticleGoogle Scholar
- Huang DW, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nature Protoc 2009, 4: 44–57.View ArticleGoogle Scholar
- Huang DW, Sherman BT, Lempicki RA: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009, 37: 1–13. 10.1093/nar/gkn923PubMed CentralView ArticleGoogle Scholar
- Thomas PD, Kejariwal A, Campbell MJ, Mi H, Diemer K, Guo N, Ladunga I, Ulitsky-Lazareva B, Muruganujan A, Rabkin S, Vandergriff JA, Doremieux O: PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res 2003, 31: 334–341. 10.1093/nar/gkg115PubMed CentralPubMedView ArticleGoogle Scholar
- Mi H, Dong Q, Muruganujan A, Gaudet P, Lewis S, Thomas PD: PANTHER version 7: improved phylogenetic trees, orthologs and collaboration with the Gene Ontology Consortium. Nucleic Acids Res 2010, 38: D204-D210. 10.1093/nar/gkp1019PubMed CentralPubMedView ArticleGoogle Scholar
- del Val C, Ernst P, Falkenhahn M, Fladerer C, Glatting KH, Suhai S, Hotz-Wagenblatt A: ProtSweep, 2DSweep and DomainSweep: protein analysis suite at DKFZ. Nucleic Acids Res 2007, 35: W444–450. 10.1093/nar/gkm364PubMed CentralPubMedView ArticleGoogle Scholar
- Shitama T, Hayashi H, Noge S, Uchio E, Oshima K, Haniu H, Takemori N, Komori N, Matsumoto H: Proteome profiling of vitreoretinal diseases by cluster analysis. Proteomics Clin Appl 2008, 2: 1265–1280. 10.1002/prca.200800017PubMed CentralPubMedView ArticleGoogle Scholar
- Gao BB, Chen X, Timothy N, Aiello LP, Feener EP: Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. J Proteome Res 2008, 7: 2516–2525. 10.1021/pr800112gPubMedView ArticleGoogle Scholar
- Smiddy WE, Michels RG, Green WR: Morphology, pathology, and surgery of idiopathic vitreoretinal macular disorders. A review. Retina 1990, 10: 288–296.Google Scholar
- Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, Veenstra TD, Adkins JN, Pounds JG, Fagan R, Lobley A: The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 2004, 3: 311–326. 10.1074/mcp.M300127-MCP200PubMedView ArticleGoogle Scholar
- Lyngholm M, Vorum H, Nielsen K, Ehlers N, Honoré B: Attempting to distiguish between endogenous and contaminating cytokeratins in a corneal proteomic study. BMC Ophthalmol 2011, 11: 3. 10.1186/1471-2415-11-3PubMed CentralPubMedView ArticleGoogle Scholar
- Fort PE, Lampi KJ: New focus on alpha-crystallins in retinal neurodegenerative diseases. Exp Eye Res 2011, 92: 98–103. 10.1016/j.exer.2010.11.008PubMed CentralPubMedView ArticleGoogle Scholar
- Wiesner J, Vilcinskas A: Antimicrobial peptides: the ancient arm of the human immune system. Virulence 2010, 1: 440–464. 10.4161/viru.1.5.12983PubMedView ArticleGoogle Scholar
- You J, Fitzgerald A, Cozzi PJ, Zhao Z, Graham P, Russell PJ, Walsh BJ, Willcox M, Zhong L, Wasinger V, Li Y: Post-translation modification of proteins in tears. Electrophoresis 2010, 31: 1853–1861. 10.1002/elps.200900755PubMedView ArticleGoogle Scholar
- Schloetzer-Schrehardt U, André S, Janko C, Kaltner H, Kopitz J, Gabius HJ, Herrmann M: Adhesion/growth regulatory galectins in the human eye: localization profiles and tissue reactivities as standard to detect disease-associated alterations. Graefes Arch Clin Exp Ophthalmol 2012, 250: 1169–1180. 10.1007/s00417-012-2021-9View ArticleGoogle Scholar
- Wyatt K, Gao C, Tsai JY, Fariss RN, Ray S, Wistow G: A role for lengsin, a recruited enzyme, in terminal differentiation in the vertebrate lens. J Biol Chem 2008, 283: 6607–6615. 10.1074/jbc.M709144200PubMed CentralPubMedView ArticleGoogle Scholar
- Hindson VJ, Gallagher JT, Halfter W, Bishop PN: Opticin binds to heparan and chondroitin sulfate proteoglycans. Invest Ophthalmol Vis Sci 2005, 46: 4417–4423. 10.1167/iovs.05-0883PubMedView ArticleGoogle Scholar
- Grayson C, Reid SN, Ellis JA, Rutherford A, Sowden JC, Yates JR, Farber DB, Trump D: Retinoschisin, the X-linked retinoschisis protein, is a secreted photoreceptor protein, and is expressed and released by Weri-Rb1 cells. Hum Mol Genet 2000, 9: 1873–1879. 10.1093/hmg/9.12.1873PubMedView ArticleGoogle Scholar
- Wistow G, Bernstein SL, Wyatt MK, Behal A, Touchman JW, Bouffard G, Smith D, Peterson K: Expressed sequence tag analysis of adult human lens for the NEIBank Project: over 2000 non-redundant transcripts, novel genes and splice variants. Mol Vis 2002, 8: 171–184.PubMedGoogle Scholar
- An E, Lu X, Flippin J, Devaney JM, Halligan B, Hoffman EP, Strunnikova N, Csaky K, Hathout Y: Secreted proteome profiling in human RPE cell cultures derived from donors with age related macular degeneration and age matched healthy donors. J Proteome Res 2006, 5: 2599–261. 10.1021/pr060121jPubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.